Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-13-66 | Oral Session 13: Basic 3 | ETA2022

Generation of human thyroid organoids from embryonic stem cells to rescue hypothyroidism

Romitti Mirian , Tourneur Adrien , Lasolle Helene , Detours Vincent , Singh Sumeet , Refetoff Samuel , Costagliola Sabine

Organoids are tiny, self-organized three-dimensional versions of an organ that are produced in vitro. Human organoids offer unique opportunities to model the development, physiology, and diseases of human tissues while complementing animal models and reducing the need for animal testing. In the thyroid field, there is a lack of a functional human in vitro thyroid model which allows to further explore various aspects related to thyroid development and disease....

ea0063gp172 | Obesity (1) | ECE2019

Pituitary surgery as first-line therapy for microprolactinomas

Teulade Marie , Lasolle Helene , Vasiljevic Alexandre , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald

Introduction: Dopamine agonists (DA), reference treatment for microprolactinomas, rarely allow long term remission. The performance of endoscopic pituitary surgery should be examined as first-line treatment.Objective: To evaluate the remission rate of microprolactinoma operated by endoscopic transphenoidal approachMethods: We retrospectively studied the surgical results of the 35 microprolactinomas operated between 2010 to 2017 in ...

ea0056p870 | Pituitary - Clinical | ECE2018

Safety and efficacy of long-acting Pasireotide monotherapy in acromegalic patients treated with a combination of first-generation somatostatin analogs and cabergoline or pegvisomant

Lasolle Helene , Ferriere Amandine , Nunes Marie-Laure , Haissaguerre Magalie , Tabarin Antoine

Introduction: Combination therapy using pegvisomant and cabergoline with first-generation long-acting somatostatin analogs (1GSSA) is a common procedure in acromegalic patients that are not fully controlled by surgery and 1GSSA. Pasireotide-LAR is a new multireceptor-targeted somatostatin receptor ligand that has superior efficacy over octreotide LAR to control GH and IGF1 levels. Little data is available about the efficacy and safety of pasireotide monotherapy in patients tre...

ea0084op-01-06 | Oral Session 1: Topic Highlights | ETA2022

Modeling braf-induced thyroid cancer development and cell redifferentiation using pluripotent stem cell-derived organoids

Lasolle Helene , Gillotay Pierre , Ceolin Lucieli , Aganahi Benilda , Malta Letro Kizys Marina , Luiza Maia Ana , Costagliola Sabine , Romitti Mirian

Introduction: Due to their remarkable self-organizing structures and functional properties, organoid has become a powerful tool to model diseases ‘in a dish’. The use of organoids in cancer research emerged to better understand tumor behavior. Originally, adult stem cells (aSC)-derived organoids were derived from primary tumors while recent studies have reported the generation of cancer models arising from healthy cells by controlling oncogene expression. SC-derived ...

ea0056p784 | Pituitary - Basic | ECE2018

CGH array analysis of pituitary tumors revealed a highly-disrupted genome

Lasolle Helene , Elsensohn Mad-Helenie , Alix Eudeline , Bonnefille Clement , Michel Jessica , Bardel Claire , Roy Pascal , Sanlaville Damien , Raverot Gerald

Introduction: Genetic of pituitary tumors (PT) is incompletely understood. The aim of this study was to search for somatic copy number variations (CNV) in pituitary tumors and evaluate their prognostic impact on tumor recurrence.Methods: CGH array analysis (Agilent SurePrint G3 Human CGH+SNP Microarray 4×180 K) was performed on 196 fresh-frozen PT (67 gonadotroph, 31 corticotroph, 38 prolactinomas, 60 somatotroph). PT were classified according to th...

ea0041gp235 | Thyroid Cancer (1) | ECE2016

Thyroid nodules: a highly specific molecular and cytological combined predictor of malignancy

Lasolle Helene , Riche Benjamin , Decaussin Myriam , Dantony Emmanuelle , Cornu Catherine , Lifante Jean-Christophe , Capraru Oana-Maria , Rousset Bernard , Borson-Chazot Francoise , Roy Pascal

Thyroid nodules are very common and benign in most cases. Thus, malignancy detection avoiding overtreatment is a challenge. Nodule evaluation mainly supports on US and fine needle aspiration cytology (FNAC). The Bethesda classification (BC) for reporting thyroid cytopathology is now currently used for the interpretation of results but it does not enable classifying 30% of samples.The objective was to identify, by transcriptome analysis, a molecular signa...

ea0081p400 | Pituitary and Neuroendocrinology | ECE2022

European Registries for Rare Endocrine Conditions (EuRRECa): results from the core registry on hypothalamic and pituitary conditions

Luisa Priego Zurita Ana , Appelman-Dijkstra Natasha , Biermasz Nienke , Bryce Jillian , Burman Pia , Castano Luis , Dattani Mehul , Dekkers Olaf M. , Fibbi Benedetta , Gan Hoong-Wei , Gaztambide Sonia , Haeusler Gabriele , Haufler Florentina , Katugampola Harshini , Helene Lasolle , L Muller Hermann , Raverot Gerald , Rica Itxaso , van Beuzekom Charlotte , Sumnik Zdenek , de Vries Friso , Zamanipoor Najafabadi Amir , Ahmed Faisal , M Pereira Alberto

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) was created in collaboration with the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Paediatric Endocrinology and the European Society of Endocrinology to support the needs of the endocrine community. The Core Registry, one of its platforms, enables the collection of longitudinal patient and clinician reported outcomes. A module collecting aspects of the ...

ea0037gp.30.01 | Endocrine tumours and neoplasia – General | ECE2015

Temozolomide treatment for pituitary aggressive tumours and pituitary carcinomas: initial results and long-term follow-up of a cohort of 32 cases

Lasolle Helene , Castinetti Frederic , Cortet Christine , Cloix Lucie , Batisse-Lignier Marie , Bonnet Fabrice , Bourcigaux Nathalie , Chabre Olivier , Chanson Philippe , Delemer Brigitte , Lebrun-Frenay Christine , Garcia Cyril , Reznik Yves , Schillo Franck , Taillandier Luc , Maiter Dominique , Sadoul Jean-Louis , Caron Philipe , Raverot Gerald

Context: Successful used of temozolomide (TMZ) treatment has been described in 40–50% of aggressive pituitary tumour (PT) or rare pituitary carcinoma. These results are based on 50 case-reports and small series, data on long-term follow-up being rare.Objectives: To describe initial results and long-term follow-up of a large French cohort of patients presenting PT treated with temozolomide.Design: Members of the French Society ...